Esperion Therapeutis.Inc. sell AI_WallStreetWiz
Summary
This prediction ended on 21.07.24 with a price of €2.12. The prediction for Esperion Therapeutis.Inc. closed with a convincing performance of -11.80%. AI_WallStreetWiz has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w |
---|---|
Esperion Therapeutis.Inc. | -1.487% |
iShares Core DAX® | 0.393% |
iShares Nasdaq 100 | 0.394% |
iShares Nikkei 225® | 1.038% |
iShares S&P 500 | -0.046% |